Dr. Rachel Parker -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Rachel Parker, a Rheumatology physician based in Jersey City, NJ. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Rachel Parker has received $42,223.99 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Rachel Parker
- Medical Specialty: Rheumatology
- Practice Location: Jersey City, NJ, New Jersey
- NPI Number: 1217716706
- Transparency Score: 50/100
- Payment Records Span: 2025-07-06 to 2025-07-06
Payment Summary
Dr. Rachel Parker has received a total of $42,223.99 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $42,223.99 per transaction.
- Total Payments Received: $42,223.99
- Number of Transactions: 1
- Average Payment: $42,223.99
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Rheumatology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
Payment Breakdown by Category
The following table shows how Dr. Rachel Parker's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Speaking & Education | $42,223.99 | Promotional speaking, CME events, and educational presentations |
The largest payment category for Dr. Rachel Parker is Speaking & Education, accounting for 100% ($42,223.99) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Rachel Parker. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| AbbVie Inc | $42,223.99 | 1 |
Dr. Rachel Parker has a financial relationship with AbbVie Inc, receiving $42,223.99 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Rachel Parker's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. Rachel Parker, a Rheumatologist in Jersey City, NJ, has a pharmaceutical payment profile characterized by a single, substantial payment totaling $42,223.99. This payment originates from AbbVie Inc. and is designated for speaking engagement activities scheduled for July 6, 2025. When compared to the broader landscape of Rheumatology, this payment volume is notably high for a single event, though the overall frequency of payments is extremely low (only one recorded instance). The concentration of the entire payment amount from a single company, AbbVie Inc., suggests a focused relationship. AbbVie is a major pharmaceutical company with a significant presence in the rheumatology space, marketing several key drugs for conditions like rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. This single, large speaking fee indicates a potential role as an educator or influencer within the medical community regarding AbbVie's products or related therapeutic areas. The payment type is exclusively 'speaking,' which falls under the category of professional services. While speaking engagements can be a legitimate way for pharmaceutical companies to disseminate information about new treatments and research findings to healthcare professionals, a single, high-value payment like this, especially in advance, warrants careful consideration. It is not indicative of routine professional activity in terms of frequency, but rather a significant engagement. For patients, understanding these relationships is crucial. While a doctor's engagement with pharmaceutical companies can facilitate access to cutting-edge information and potentially improve patient care through education, it also raises questions about potential influence on prescribing habits. Patients should be aware that such payments exist and engage in open dialogue with their doctors about treatment options and the rationale behind them. The key is transparency and ensuring that treatment decisions are always based on the patient's best interests, clinical evidence, and shared decision-making, rather than solely on promotional activities.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Rachel Parker is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
It's important for patients to understand that pharmaceutical companies often compensate healthcare providers for various professional activities, such as speaking at educational events, consulting, or participating in research. These relationships are not inherently negative and can sometimes lead to better-informed physicians who are up-to-date on the latest treatments. However, it's wise to be aware of these financial ties. At your next appointment, consider asking your doctor if they have any financial relationships with pharmaceutical companies whose medications you are taking or being considered for. You might ask, 'Are there any financial relationships you have with the companies that make the medications we're discussing?' or 'How do you stay informed about new treatments, and are there any potential conflicts of interest I should be aware of?' A red flag might be if a doctor seems overly enthusiastic about a particular drug without a clear clinical justification or if they dismiss alternative treatments without thorough consideration. Normal relationships often involve smaller, more frequent payments for legitimate educational or advisory roles. Concerning relationships might involve very large sums, especially for speaking or consulting, or a pattern of exclusively promoting a narrow range of products. Evaluate your doctor's prescribing patterns by looking at whether they consistently prescribe brand-name drugs when equally effective generics are available, or if their choices align with current evidence-based guidelines. Transparency is key, and open communication with your doctor about these financial disclosures can foster trust and ensure your care is patient-centered.
Peer Comparison: How Dr. Rachel Parker Compares to Other Rheumatology Physicians
The average Rheumatologist receives payments from pharmaceutical companies that can range from a few hundred to several thousand dollars annually, often spread across multiple smaller transactions for meals, consulting, or speaking. Dr. Parker's single payment of $42,223.99 significantly exceeds the typical annual volume for most rheumatologists. While the frequency is exceptionally low (one payment), the amount is substantial, placing her in a higher tier for total payment volume in a given year, particularly for a speaking engagement.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Rachel Parker in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| AbbVie Inc | $42,223.99 | speaking | N/A | 2025-07-06 | Not Assessed |
Frequently Asked Questions About Dr. Rachel Parker's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. Rachel Parker taking too much pharma money?
Dr. Parker has received a single payment of $42,223.99 from AbbVie Inc. for a speaking engagement. While this amount is substantial for a single event and significantly higher than the average annual payment for many rheumatologists, it is important to note that this is her only recorded payment. The frequency is extremely low. The payment is for a specific professional activity (speaking), which is a common practice. Whether this is 'too much' is subjective and depends on the context of the engagement and its potential influence. However, given the single nature of the payment, it doesn't suggest a pervasive pattern of financial reliance on pharmaceutical companies.
What pharma companies pay Dr. Rachel Parker?
Dr. Rachel Parker receives payments exclusively from AbbVie Inc. The total amount paid by AbbVie Inc. is $42,223.99.
Should I switch doctors because of pharma payments?
Switching doctors solely based on pharmaceutical payments is generally not recommended unless you have specific concerns about your care. Many physicians have some form of relationship with pharmaceutical companies, which can be legitimate for educational purposes. Focus on your doctor's overall quality of care, communication, and whether you feel your treatment decisions are made in your best interest. If you have concerns about a specific payment or relationship, discuss it openly with your doctor. If the conversation doesn't alleviate your concerns or if you observe a pattern of prescribing that seems influenced by these relationships, then considering a change might be warranted.
What kinds of payments does this doctor receive?
Dr. Parker's payment profile consists solely of a speaking fee. The total amount received for speaking is $42,223.99. There are no recorded payments for consulting, meals, travel, research, or ownership interests.
How do these payments compare to other Rheumatology?
The average Rheumatologist typically receives payments that are much lower in total volume and are often distributed across multiple, smaller transactions for various activities. Dr. Parker's single payment of $42,223.99 for speaking is significantly higher than the average annual total for her specialty. While the frequency is exceptionally low, the amount itself places her in a higher bracket for total payment volume in a given year, particularly for a single speaking engagement.
Do pharma payments affect prescribing quality?
Research on the impact of pharmaceutical payments on prescribing habits is complex and shows mixed results. Some studies suggest that even small payments can influence prescribing patterns, leading to increased use of brand-name drugs or newer, more expensive medications. Other studies indicate that physicians who engage with pharmaceutical companies may be more up-to-date on new treatments. The key is that these payments can create a perception of bias, even if not consciously intended. Patients should always discuss treatment options, including generics versus brand names, and the rationale behind prescribing decisions with their doctor.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. This is a public database that lists payments made by pharmaceutical and medical device companies to physicians and teaching hospitals. You can search for Dr. Rachel Parker by her National Provider Identifier (NPI) number, which is 1217716706, or by her name and location. The database provides detailed information on the payer, payee, amount, and nature of the payment.
Understanding This Doctor Payment Report
This transparency report for Dr. Rachel Parker is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Rheumatology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Rachel Parker's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Rachel Parker and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Rheumatology Specialty Payment Data -- See payment patterns for all rheumatology physicians
- New Jersey Physician Payments -- Browse pharmaceutical payments to physicians in New Jersey
- Rheumatology Physicians in New Jersey -- Compare Dr. Rachel Parker to peers in the same state and specialty
- AbbVie Inc Payment Profile -- View all payments made by Dr. Rachel Parker's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Rachel Parker's NPI (1217716706) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.